A filing for a Hong Kong IPO by Nanjing Nuo Ling Bio-Technology Co., Ltd. (referred to as Nuo Ling Bio) has expired, as the six-month validity period for the prospectus submitted on February 13, 2026, ended on August 13, 2026. At the time of submission, CCB International served as the sole sponsor.

According to the previously disclosed prospectus, Nuo Ling Bio focuses on the research, development, and commercial application of inhaled nitric oxide (iNO) therapy. Data from Frost & Sullivan indicates that Nuo Ling Bio is one of the few companies globally capable of achieving independent control over the entire NO technology chain, and it is also the only enterprise worldwide with a comprehensive product line covering both NO therapy and diagnostic applications.

As of the latest practicable date, Nuo Ling Bio had five approved products and four pipeline candidate products. These cover critical care, ward, outpatient, and home disease management within the cardiopulmonary diagnosis and treatment field, spanning three main product lines: (i) iNO therapy, (ii) cardiopulmonary circulatory support, and (iii) breath diagnostics.